Abstract
Risk sharing agreements are becoming an increasingly common type of contract between drug manufacturers and third party payers such as private insurance companies and public sector health plans. In a risk sharing agreement a payer will agree to include a drug on its formulary in the presence of a contract that reduces some of the payer’s risk. Payer risk may be caused by high uncertainty in sales volume, cost, effectiveness, or cost-effectiveness of a new drug. In this chapter we review the literature on risk sharing agreements, identify some opportunities for future research in the area, and highlight some policy implications associated with their use.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ontario Ministry of Health (2008) Ontario Drug Benefit Formulary/Comparative Drug Index No. 41. Queen’s Printer for Ontario, Toronto
Tilson L, Barry M (2005) European pharmaceutical pricing and reimbursement strategies. National Centre for Pharmacoeocnomics, Dublin, Ireland, p 166
Taylor RS et al. (2004) Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. BMJ 329:972–975
OECD (2005) Drug spending in OECD countries up by nearly a third since 1998, according to new OECD data. http://www.oecd.org/document/25/0,2340,en_2649_201185_34967193_1_1_1_1,00.html. Accessed 15 Nov 2011
OECD (2011) Quarterly National Accounts MetaData: Quarterly Growth Rates of real GDP, change over previous quarter. http://www.oecd.org/document/25/0,2340,en_2649_201185_34967193_1_1_1_1,00.html. Accessed 23 Nov 2011
Sullivan R et al. (2011) Delivering affordable cancer care in high-income countries. Lancet Oncol 12(10):933–980
Lowry F (2010) Erlotinib for advanced NSCLC is “marginally” cost effective. Medscape Medical News. http://www.medscape.com/viewarticle/717585. Accessed 15 Nov 2011
Towse A, Garrison LP Jr (2010) Can’t get no satisfaction? Will pay for performance help? Toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products. Pharmacoeconomics 28(2):93–102
Carlson JJ et al. (2010) Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy 96(3):179–190
Adamski J et al. (2010) Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res 10:153
BBC News (2009) Green light for bowel cancer drug. http://news.bbc.co.uk/2/hi/health/8077515.stm. Accessed 15 Nov 2011
Devlin K (2009) Kidney cancer patients should get Sutent on the NHS, says NICE. In: The Telegraph. London. http://www.telegraph.co.uk/health/healthnews/4449605/Kidney-cancer-patients-should-get-Student-on-the-NHS-says-NICE.html. Accessed 7 Feb 2013
BBC News (2009) Deal reached on NHS myeloma drug. http://news.bbc.co.uk/2/hi/health/7859053.stm. Accessed 15 Nov 2011
BBC News (2007) Cancer-drug refund scheme backed. http://news.bbc.co.uk/2/hi/6713503.stm
Wilkinson E (2010) NHS missing out on cancer drug payments. BBC News, London
Schuler C, Faulker LP (2009) Pay for play. PharmaExec.com
Pollack A (2007) Pricing pills by the results. New York Times, New York
National Institute for Clinical Excellence (2002) Technology appraisal No. 32. Guidance on the use of beta interferon and glatiramer acetate for the treatment of multiple sclerosis. National Institute for Clinical Excellence, London, UK, p 25
Rafferty J (2010) Multiple sclerosis risk sharing scheme: a costly failure. BMJ 340:c1672
McCabe C et al. (2010) Continuing the multiple sclerosis risk sharing scheme is unjustified. BMJ 340:c1786
Ebers GC (2010) Commentary: Outcome measures were flawed. BMJ 340:c2693
Zaric GS, O’Brien BJ (2005) Analysis of a pharmaceutical risk sharing agreement based on the purchaser’s total budget. Health Econ 14(8):793–803
Zaric GS, Xie B (2009) A comparison of two risk sharing agreements. Value in Health 12(5):838–845
Zhang H, Zaric GS (2011) Promotion and leakage under a pharmaceutical price-volume agreement. INFOR 49(4):247–253
Mahjoub R, Odegaard FK, Zaric GS (2011) Modeling the dynamics of a risk sharing agreement. INFORMS Healthcare, Montreal
Lilico A (2003) Risk-sharing pricing models in the distribution of pharmaceuticals. Staff Working Paper. Europe Economics, London
Barros PP (2011) The simple economics of risk-sharing agreements between the nhs and the pharmaceutical industry. Health Econ 20(4):461–470
Antonanzas F, Juarez-Castello C, Rodriguez-Ibeas R (2011) Should health authorities offer risk-sharing contracts to pharmaceutical firms? A theoretical approach. Health Econ Policy Law 6(3):391–403
Gandjour A (2009) Pharmaceutical risk sharing agreements. Pharmacoeconomics 27(5):431–432
Zhang H, Huang T, Zaric GS (2011) Optimal design of a price volume agreement in the presence of unobservable marketing effort. Working paper
Zhang H, Zaric GS, Huang T (2011) Optimal design of a pharmaceutical price-volume agreement under asymmetric information about expected market size. Prod Oper Manage 20(3):334–346
Cook JP, Vernon JA, Manning R (2008) Pharmaceutical risk-sharing agreements. Pharmacoeconomics 26(7):551–556
de Pouvourville G (2006) Risk-sharing agreements for innovative drugs: a new solution to old problems? Eur J Health Econ 7(3):155–157
Neumann PJ et al. (2011) Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement. Health Aff (Millwood) 30(12):2329–2337
Robertson J, Walkom EJ, Henry DA (2009) Transparency in pricing arrangements for medicines listed on the Australian Pharmaceutical Benefits Scheme. Aust Health Rev 33(2):192–199
Williamson S (2010) Patient access schemes for high-cost cancer medicines. Lancet Oncol 11(2):111–112
Dana JD, Spier KE (2001) Revenue sharing and vertical control in the video rental industry. J Ind Econ 49(3):223–245
Cachon GP, Lariviere MA (2001) Contracting to assure supply: how to share demand forecasts in a supply chain. Manage Sci 47(5):629–646
Jena AB, Philipson TJ (2008) Cost-effectiveness analysis and innovation. J Health Econ 27(5):1224–1236
Pearson SD (2007) Getting the innovation we want. Health Aff (Millwood) 26(5):1506–1507
Ingram J (2011) Eliminating innovation: how price controls limit access. J Leg Med 32(1):115–128
Scherer FM (2009) Price controls and global pharmaceutical progress. Health Aff (Millwood) 28(1):161–164
Lakdawalla DN et al. (2009) US pharmaceutical policy in a global marketplace. Health Aff (Millwood) 28(1):138–150
Garber AM, McClellan MB (2007) Satisfaction guaranteed—“Payment by Results” for biologic agents. N Engl J Med 357:1575–1577
Garrison LP et al. (2008) Paying for pills by result: Performance-based rewards for innovation. ISPOR Annual Meeting, Toronto
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Zaric, G.S., Zhang, H., Mahjoub, R. (2013). Modeling Risk Sharing Agreements and Patient Access Schemes. In: Zaric, G. (eds) Operations Research and Health Care Policy. International Series in Operations Research & Management Science, vol 190. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6507-2_14
Download citation
DOI: https://doi.org/10.1007/978-1-4614-6507-2_14
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-6506-5
Online ISBN: 978-1-4614-6507-2
eBook Packages: Business and EconomicsBusiness and Management (R0)